A clinical trial involving liraglutide has reached completed status as of October 23, 2026. The trial, registered as NCT04324229 and titled "Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes," was listed with a phase designation of not applicable.
According to the registry entry, the trial's status is now marked as completed. The study focused on liraglutide in the context of preventing type 2 diabetes in individuals with a history of gestational diabetes. No results have been reported in this update, and this brief does not characterize any outcomes, efficacy, or safety findings from the trial.
Liraglutide is an approved compound, and this trial update reflects only a change in the study's status on the registry as of the date listed. Further details regarding the trial design, enrollment, or eventual results would be available through the official clinical trial registry listing.
Readers interested in additional background on liraglutide can consult the compound overview for further context.